BACKGROUND: Prophylaxis with hepatitis B immunoglobulin (HBIG) and nucleoside analogs can prevent hepatitis B virus (HBV) recurrence after liver transplant (LT). AIM: To determine the efficacy and cost of maintaining immunoprophylaxis with HBIG and hyperimmune plasma (HIP) for 6 months after LT. MATERIAL & METHODS: The study included 22 HBV related LT recipients who were on entecavir and either HBIG or HIP for 6 months. Post transplant HBIG or HIP dose and cost incurred towards prophylaxis were noted. The cost of 200 IU of HBIG at the time of study was Rs 8250/- (US Dollars 135) and that of 2000 IU of HIP was Rs 8000/- (USD 130.7). The loading and maintenance costs at end of 6 months were compared between the two groups. Response to HBIG and HIP was assessed by checking for HBsAg reactivity, anti HBs titer response and HBV DNA viral load. STATISTICAL ANALYSIS: Median and range, Kruskal Wallis (KW) sign rank Sum Test and Correlation Coefficient (r2) was used for analysis. RESULTS: Thirteen recipients received HBIG and 9 recipients HIP. The anti HBs response to HIP was significantly high compared to HBIG (KW Sign rank Sum test P < 0.05); titers remained high until the study period. Between 8 and 30 days, the titer achieved by both HBIG and HIP was similar (KW Sign rank Sum test not significant). Despite low anti HBs titer of <100 IU/L, none of the recipients on HBIG had HBsAg reactivity while 3 on HIP had transient HBsAg positivity. The total cost with HBIG was 13.9 times the cost of HIP. CONCLUSION: HIP immunoprophylaxis in combination with entecavir achieves a high anti HBs titer at a significant low cost during anhepatic and loading phase. HBV reactivation rates with HBIG and HIP is low despite low anti HBs titer.
BACKGROUND: Prophylaxis with hepatitis B immunoglobulin (HBIG) and nucleoside analogs can prevent hepatitis B virus (HBV) recurrence after liver transplant (LT). AIM: To determine the efficacy and cost of maintaining immunoprophylaxis with HBIG and hyperimmune plasma (HIP) for 6 months after LT. MATERIAL & METHODS: The study included 22 HBV related LT recipients who were on entecavir and either HBIG or HIP for 6 months. Post transplant HBIG or HIP dose and cost incurred towards prophylaxis were noted. The cost of 200 IU of HBIG at the time of study was Rs 8250/- (US Dollars 135) and that of 2000 IU of HIP was Rs 8000/- (USD 130.7). The loading and maintenance costs at end of 6 months were compared between the two groups. Response to HBIG and HIP was assessed by checking for HBsAg reactivity, anti HBs titer response and HBV DNA viral load. STATISTICAL ANALYSIS: Median and range, Kruskal Wallis (KW) sign rank Sum Test and Correlation Coefficient (r2) was used for analysis. RESULTS: Thirteen recipients received HBIG and 9 recipients HIP. The anti HBs response to HIP was significantly high compared to HBIG (KW Sign rank Sum test P < 0.05); titers remained high until the study period. Between 8 and 30 days, the titer achieved by both HBIG and HIP was similar (KW Sign rank Sum test not significant). Despite low anti HBs titer of <100 IU/L, none of the recipients on HBIG had HBsAg reactivity while 3 on HIP had transient HBsAg positivity. The total cost with HBIG was 13.9 times the cost of HIP. CONCLUSION:HIP immunoprophylaxis in combination with entecavir achieves a high anti HBs titer at a significant low cost during anhepatic and loading phase. HBV reactivation rates with HBIG and HIP is low despite low anti HBs titer.
Entities:
Keywords:
ESLD, end-stage liver disease; HBIG, hepatitis B immunoglobulin; HBV recurrence; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIP, hyper-immune plasma; HIV, human immunodeficiency virus; Hepatitis B virus; KW, Kruskal Wallis; LT, liver transplantation; NA, nucleos(t)ide analogs; USD, US Dollars; anti HBs Ab, anti hepatitis B virus antibody; hepatitis B immunoglobulin; hyper-immune plasma; liver transplantation
Authors: G Mentha; E Giostra; F Negro; L Rubbia-Brandt; O Huber; A Hadengue; L Perrin; P Morel Journal: Transplant Proc Date: 1997-08 Impact factor: 1.066
Authors: James Fung; Cindy Cheung; See-Ching Chan; Man-Fung Yuen; Kenneth S H Chok; William Sharr; Wing-Chiu Dai; Albert C Y Chan; Tan-To Cheung; Simon Tsang; Banny Lam; Ching-Lung Lai; Chung-Mau Lo Journal: Gastroenterology Date: 2011-07-14 Impact factor: 22.682
Authors: N V Naoumov; A R Lopes; P Burra; L Caccamo; R M Iemmolo; R A de Man; M Bassendine; J G O'Grady; B C Portmann; G Anschuetz; C A Barrett; R Williams; M Atkins Journal: J Hepatol Date: 2001-06 Impact factor: 25.083
Authors: Edward J Gane; Peter W Angus; Simone Strasser; Darrell H G Crawford; John Ring; Gary P Jeffrey; Geoffrey W McCaughan Journal: Gastroenterology Date: 2007-01-05 Impact factor: 22.682
Authors: Peter W Angus; Scott J Patterson; Simone I Strasser; Geoffrey W McCaughan; Edward Gane Journal: Hepatology Date: 2008-11 Impact factor: 17.425